First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Delva R, Sevin E, Négrier S, McKendrick J, Santoro A, Pisa P, Escudier B.
Melichar B, et al.
Ann Oncol. 2008 Aug;19(8):1470-1476. doi: 10.1093/annonc/mdn161. Epub 2008 Apr 11.
Ann Oncol. 2008.
PMID: 18408224
Free article.
Clinical Trial.